What is claimed is:

1. A composition comprising a conditioned medium derived from mesenchymal stem cells of the umbilical cord obtained or obtainable by a method of producing a conditioned medium, the method comprising:
   (a) cultivating mesenchymal stem cells of the umbilical cord, wherein the mesenchymal stem cells of the umbilical cord are derived from a mesenchymal stem cell population of the amniotic membrane of the umbilical cord or from a mesenchymal stem population of the Wharton's jelly of the umbilical cord, in a culture medium comprising DMEM (Dulbecco's modified eagle medium), F12 (Ham's F12 Medium), M171 (Medium 171) and FBS (Fetal Bovine Serum), wherein the culture medium comprises DMEM in a final concentration of 55 to 65 % (v/v), F12 in a final concentration of 5 to 15 % (v/v), M171 in a final concentration of 15 to 30 % (v/v) and FBS in a final concentration of 1 to 8 % (v/v);
   (b) removing the mesenchymal stem cells of the umbilical cord from the culture medium;
   (c) cultivating the mesenchymal stem cells of the umbilical cord in a further culture medium, wherein the further medium is a basal medium suitable for cultivation of mesenchymal stem cells and wherein the further cell culture medium comprises a water-soluble antioxidant,

   wherein the conditioned medium is obtained by collecting the cell culture medium,

   and wherein the composition further comprises a solvent/carrier, wherein the solvent/carrier is water or an aqueous buffer solution.

2. The composition of claim 1, wherein the culture medium used in step (a) comprises DMEM in a final concentration of 57.5 to 62.5 % (v/v), F12 in a final concentration of 7.5 to 12.5 % (v/v), M171 in a final concentration of 17.5 to 25.0 % (v/v) and FBS in a final concentration of 1.75 to 3.5 % (v/v).

3. The composition of claim 1 or 2, wherein the further cell culture medium used in step (c) does not comprise a growth factor and/or is a serum-free medium and/or

wherein the cells are cultivated at a concentration of about 1 million cells per 1 ml.

4. The composition of any of claims 1 to 3, wherein the mesenchymal stem cells of the umbilical cord are human or red deer mesenchymal stem cells of the umbilical cord.

5. The composition of any of claims 1 to 4, wherein the further medium used in step (c) is selected from the group consisting of Dulbecco's Modified Eagle Medium (DMEM), DMEM-F12, RPMI media, EpiLIfe medium, and Medium 171.

6. The composition of any of claims 1 to 5, wherein the composition further comprises an anti-inflammatory compound.

7. The composition of claim 6, wherein the anti-inflammatory compound is selected from the group consisting of curcumin, sulfacetamide, a non-steroidal anti-inflammatory compound, niacinamide (vitamin B3), calendula, sea buckthorn oil, chamomile extract, an extract of Centella asiatica and mixtures thereof.

8. The composition of claim 6 or 7, wherein the composition further comprises a humectant.

9. The composition of claim 8, wherein the humectant is selected from the group consisting of glycerine, propylene glycol, triethylene glycol, tripropylene glycol, sorbitol, hexylene glycol, butylene glycol, urea, collagen and mixtures thereof.

10. The composition of claim 9, wherein the humectant comprises glycerine, propylene glycol or both glycerine and propylene glycol.

11. The composition of any of claims 1 to 10, wherein the composition comprises the conditioned medium derived from cultivation of mesenchymal stem cells of the umbilical cord in an amount of 5 to 40 % (v/v) of the total volume of the composition, the humectant in amount of 10 to 30 % (v/v) of the total volume of the composition, and the anti-inflammatory compound in an amount of 1.0 to

3.0 % (v/v) of the composition or in an amount of 0.5 to 5.0 % (w/w) of the total weight of the composition.

12. The composition of claim 11, wherein the composition comprises the conditioned medium derived from cultivation of mesenchymal stem cells of the umbilical cord in an amount of 10 to 30 % (v/v) of the total volume of the composition, the humectant in amount of 15 to 25 % (v/v) of the total volume of the composition, and the anti-inflammatory compound in an amount of 1.0 to 3.0 % (v/v) of the composition or in an amount of 0.75 to 3.0 % (w/w) of the total weight of the composition.

13. The composition of any of claim 1 to 10, wherein the composition comprises the conditioned medium derived from cultivation of mesenchymal stem cells of the umbilical cord in an amount of 5 to 40 % (w/w) of the total weight of the composition, the humectant in amount of 10 to 30 % (w/w) of the total weight of the composition, and the anti-inflammatory compound in an amount of 0.5 to 5.0 % (w/w) of the total weight of the composition.

14. The composition of any of claims 1 to 13 , wherein the composition comprises
- conditioned medium derived from cultivation of mesenchymal stem cells of the umbilical cord,
- glycerin, propylene glycol or both glycerin and propylene glycol, and
- curcumin.

15. The composition of any of claims 1 to 14, wherein the composition comprises

- water in an amount of 50 to 65 % (v/v), preferably 55 to 58 % (v/v), most preferably in an amount of 57 % (v/v) of the total volume of the composition
- glycerin in an amount of 10 to 35 % (v/v), preferably 15 to 25 % (v/v), most preferably 20 % (v/v) of the total amount of the composition
- conditioned medium in an amount of 10 to 35 % (v/v), preferably 15 to 25 % (v/v), most preferably 20 % (v/v) of the total amount of the composition,
- 1,2-hexanediol in an amount of 1 to 5.5 % (v/v), preferably 1.5 to 3.5 % (v/v), most preferably 2 % (v/v) of the total amount of the composition,
- curcumin in an amount of 0.5 to 5.0 % (w/w), preferably of 0.75 to 2.5 % (w/w), most preferably 1.0 % (w/w) of the total weight of the composition, or

wherein the composition comprises - water in an amount of 40 to 65 % (w/w), preferably 45 to 55 % (w/w), most preferably in an amount of 52 % (w/w) of the total weight of the composition,

- the conditioned medium in an amount of 5 to 40 % (w/w) of the total weight of the composition, preferably in an amount of 10 % (w/w) to 30 % (w/w) or 12.5 to 25 % (w/w), most preferably in an amount of 17.5 to 20.0 % (w/w) %,
- glycerin and/or propylene glycol in amount of 10 to 30 % (w/w) of the total weight of the composition, preferably in an amount of 10 % (w/w) to 30 % (w/w) or 12.5 to 25 % (w/w), most preferably in an amount of 17.5 to 20.0 % (w/w) of the total weight of the composition, and
- curcumin in 0.5 to 5.0 % (w/w) of the total weight of the composition, preferably 0.75 to 2.5 % (w/w) or 0.8 to 1.5 % (w/w), most preferably 0.9 to 1.0 % (w/w) of the total weight of the composition.

16. The composition of any of claims 1 to 15, wherein the composition further comprises one or more of a gelling agent, a buffering agent and an emollient.

17. The composition of claim 16, wherein the gelling agent is selected from the group consisting of a poly(acrylic acid), pectin, starch, an alginate such as sodium alginate, gelatin, a cellulose derivative and polyvinyl alcohol clay.

18. The composition of claim 16 or 17, wherein the buffering agent is selected from the group consisting of a sodium phosphate salt, calcium carbonate, sodium bicarbonate, citric acid, triethanolamine and a Good's buffer.

19. The composition of any of claims 16 to 18, wherein the emollient is selected from the group consisting of Olive Oil PEG-7 Esters, triglycerides, lanolin, polyhydric alcohols, and esters of fatty acids (e.g. isopropyl myristate, dioctyl sebecate and dioctyl maleate).

20. Use of conditioned medium derived from cultivation of mesenchymal stem cells of the umbilical cord for the manufacture of a pharmaceutical composition for inducing, stimulating and/or promoting healing of a wound or of a damaged skin

area, wherein the pharmaceutical composition comprising the conditioned medium is to be administered topically to the skin of a subject surrounding the wound or the damaged skin area.

21. The use of claim 20, wherein the use does not comprise administering the conditioned medium onto the wound or the damaged skin area.

22. The use of any of claims 20 to 21, wherein the conditioned medium is administered in the form of a gel, a cream or a liquid.

23. The use of any of claims 20 to 22, wherein the skin to be treated is diabetic skin or thin (weak) skin.

24. The use of any of claims 20 to 23, wherein the wound or damaged skin area is a chronic wound or a chronically damaged skin.

25. The use of any of claims 20 to 24, wherein the wound is selected from the group consisting of diabetic foot ulcer (DFU), pressure ulcer, a wound due to chronic limb ischemia, a wound due to chronic limb-threatening limb ischemia, venous leg ulcer, a surgical wound, a stab wound, a burn wound, and a bit wound.

26. The use of any of the preceding claims 20 to 25, wherein the conditioned medium is derived from cultivation of a mesenchymal stem cell population of the amniotic membrane of the umbilical cord, from cultivation of a mesenchymal stem population of the Wharton's jelly of the umbilical cord (WJ), from cultivation of a perivascular (PV) mesenchymal stem cell population, or from cultivation of a mixed mesenchymal stem cell population of the umbilical cord (MC).

27. The use of any of the preceding claims 20 to 26, wherein the conditioned medium is obtained or obtainable by cultivation of mesenchymal stem cells of the umbilical cord in a culture medium comprising DMEM (Dulbecco's modified eagle medium), F12 (Ham's F12 Medium), M171 (Medium 171) and FBS (Fetal Bovine Serum).

28. The use of claim 27, wherein the culture medium comprises DMEM in a final concentration of 55 to 65 % (v/v), F12 in a final concentration of 5 to 15 % (v/v), M171 in a final concentration of 15 to 30 % (v/v) and FBS in a final concentration of 1 to 8 % (v/v), or

wherein the culture medium comprises DMEM in a final concentration of 57.5 to 62.5 % (v/v), F12 in a final concentration of 7.5 to 12.5 % (v/v), M171 in a final concentration of 17.5 to 25.0 % (v/v) and FBS in a final concentration of 1.75 to 3.5 % (v/v), or

wherein the culture medium comprises DMEM in a final concentration of 61.8 % (v/v), F12 in a final concentration of 11.8 % (v/v), M171 in a final concentration of 23.6 % (v/v) and FBS in a final concentration of 2.5 % (v/v), and/or

wherein the culture medium further comprises

(i) Epidermal Growth Factor (EGF) in a final concentration of 1 ng/ml to 20 ng/ml, or

(ii) wherein the culture medium comprises EGF in a final concentration of 10ng/ml, or

(iii) wherein the culture medium comprises Insulin in a final concentration of 1 µg/ml to 10 µg/ml, or

(iv) wherein the culture medium comprises Insulin in a final concentration of 5µg/ml, or

(v) wherein the culture medium further comprises at least one of the following supplements: adenine, hydrocortisone, and 3,3′,5-Triiodo-L-thyronine sodium salt (T3), or

(vi) wherein the culture medium comprises all three of adenine, hydrocortisone, and 3,3′,5-Triiodo-L-thyronine sodium salt (T3),

wherein optionally the culture medium comprises adenine in a final concentration of 0.01 to 0.1 µg/ml adenine, hydrocortisone in a final concentration of 0.1 to 10 µg/ml hydrocortisone and/or 3,3′,5-Triiodo-L-thyronine sodium salt (T3) in a final concentration of 0.5 to 5 ng/ml.

29. The use of any of claims 26 to 28, wherein the mesenchymal stem cells of the umbilical cord are human or red deer mesenchymal stem cells of the umbilical cord.